secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106915
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track
--------------------------------------------------------------------------------

- Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.
- Net loss $37M vs $31.7M in Q2 2024; cash+equivalents+securities $218M (excl. $5M restricted).
- Expects to dose first solid tumor patients with multiplex TCR-T in Q3 2025; initial safety/response data in Q1 2026.
- Plans to initiate registrational trial for TSC-101 in H2 2025 and file IND for TSC-102-A0301 in H2 2025.
- ALL OHA Phase 1 two-year relapse data on TSC-101 to be presented by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/0000950170-25-106915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/tcrx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer